A report of the results of clinical study of the biologically active peptide bioregulator of brain origin:
The biologically active peptide bioregulator Cerluten® contains a complex of low-molecular peptides with molecular weight up to 10 000 Da, isolated from CNS of young animals - calves aged up to 12 months.
Cerluten® is manufactured in the form of capsules with a content of active substances of 10 mg.
Experimental studies have shown that the peptides possess tissue-specific action on the cells of the tissues from which they were isolated. Cerluten ® peptides regulate metabolism processes in the brain cells, increase brain safety margins, having a favorable effect on the organism adaptation processes in extreme conditions, the possess anti-oxidative properties, regulating peroxide oxidation processes in the brain cortex. So it is possible to extrapolate an efficiency of administration of Cerluten ® for restoration of the function of the central nervous system and its disorders of various origins.
Treatment of central nervous system diseases is of specific urgency, because they lead to social adaptation disorder and invalidation of patients (2).
Now the treatment of patients with disease of central nervous system diseases in view of pathogenetic mechanisms is carried out using the following traditional therapeutic agents of various action types: (1, 3)
The clinical studies of Cerluten® were carried out at the Medical Center of the Saint Petersburg Institute of Bioregulation and Gerontology of the Northwest Branch of the Russian Academy of Medical Sciences in 48 patients with various diseases of central nervous system: long-term effects of craniocerebral injury (the prescription of the injuries was from 1 year to 10 years), state after stroke, vascular encephalopathias, decrease in mental capacity, memory, attention during the period from October 2003 till February 2004. Distribution of the patients by clinical entities, sex and age is shown in the table 1. The patients of the main group have been taking Cerluten® in addition to the general purpose medicines - 1-2 capsules, 2-3 times a day before meal for 10-20 days depending on intensity of the pathological process.
The control group consisted of 37 similar patients, which have only general purpose treatment.
All the patients have been taking symptomatic and pathogenetic drugs, these drugs have resulted in short-term therapeutic effect, which required increase in a dose of the drugs per treatment course and duration of their administration.
Information on this email is provided for informational purposes and is not meant to substitute for the advice provided by your own physician or other medical professional. You should not use the information contained herein for diagnosing or treating a health problem or disease, or prescribing any medication. Statements have not been evaluated by the Food and Drug Administration.
Copyright © 2005 - 2017
Copyright © 2005 - 2017